TERT and thyroid cancer, nonmedullary, 2: Telomerase reverse transcriptase (TERT) promoter mutations are also detected in ATC (40–70%), PDTC (40%), an aggressive form of HTC (32%), PTC (10%) and FTC (20%) [7,10,37], (Figure 2, Table 1).